Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824473 | 0.91 | CYP2C19 (0.49) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL7824476 | 0.91 | CYP2C19 (0.49) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL14917860 | 0.86 | EPHX1 (0.53) | CYP2C19TBXAS1CYP2D6EPHX1LMNA | |
| SCHEMBL27264382 | 0.83 | CPN1 (0.42) | CYP2C19TBXAS1CTSSCTSKCPN1 | |
| SCHEMBL27264378 | 0.83 | CPN1 (0.42) | CTSSCTSKCPN1CPB2 | |
| SCHEMBL14360139 | 0.83 | TBXAS1 (0.60) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL14917721 | 0.81 | EPHX1 (0.51) | CYP2C19TBXAS1CYP2D6EPHX1LMNA | |
| Ammonia Solution, Strong SCHEMBL28556745 | 0.81 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28562956 | 0.81 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL30371912 | 0.80 | CYP2C19 (0.61) | CYP2C19TBXAS1CYP2D6SRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CYP2C19 3902/4885TBXAS1 864/4885CYP2D6 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.